PUBLISHER: The Business Research Company | PRODUCT CODE: 1658987
PUBLISHER: The Business Research Company | PRODUCT CODE: 1658987
A diabetic foot ulcer is a skin sore with full-thickness skin loss on the foot, resulting from neuropathic and vascular complications in individuals with diabetes mellitus. These ulcers impede the healing process and increase susceptibility to infections, potentially leading to serious complications, including the need for amputation if not properly addressed. Diabetic foot ulcer treatment aims to prevent, treat, and manage these ulcers in diabetic patients.
The primary types of diabetic foot ulcer treatment include wound care dressings, biologics, therapy devices, antibiotic medications, and other interventions. Wound care dressings are sterile pads used to cover wounds, promoting healing and protecting against further damage. Various types of ulcers are classified as neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcers, categorized by grades 1 through 5 based on severity. Diabetic foot ulcer treatments are utilized by hospitals, ambulatory surgery centers, and other end-users in the healthcare sector.
The diabetic foot ulcer treatment market research report is one of a series of new reports from The Business Research Company that provides diabetic foot ulcer treatment market statistics, including diabetic foot ulcer treatment industry global market size, regional shares, competitors with a diabetic foot ulcer treatment market share, detailed diabetic foot ulcer treatment market segments, market trends and opportunities, and any further data you may need to thrive in the diabetic foot ulcer treatment industry. This diabetic foot ulcer treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The diabetic foot ulcer treatment market size has grown strongly in recent years. It will grow from $7.43 billion in 2024 to $8.02 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to rising diabetes prevalence, increased awareness and early detection, improved patient education, government initiatives and healthcare policies, multidisciplinary approach to care, wound care guidelines and protocols.
The diabetic foot ulcer treatment market size is expected to see strong growth in the next few years. It will grow to $11.25 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to increasing diabetes awareness campaigns, personalized medicine approaches, patient-centric care models, value-based healthcare initiatives, continuous medical education. Major trends in the forecast period include technological advances in wound care products, multidisciplinary care teams, emphasis on offloading techniques, integration of bioactive dressings, cost-effective and outpatient treatment options, increased use of hyperbaric oxygen therapy.
The diabetic foot ulcer treatment market is poised for growth due to the rising number of diabetes patients. Diabetes, a metabolic illness with long-term effects, significantly contributes to elevated blood glucose levels, leading to substantial harm to various bodily functions. Diabetes is a major cause of foot ulcers, resulting in a heightened demand for effective diabetic foot ulcer treatment. Notably, in 2022, the Centers for Disease Control and Prevention reported around 37.3 million people in the United States suffering from diabetes, comprising 11.3% of the population. Globally, the International Diabetes Federation highlighted approximately 537 million adults with diabetes, emphasizing the considerable impact on both developed and developing countries. The increased prevalence of diabetes is a key factor propelling the growth of the diabetic foot ulcer treatment market.
The diabetic foot ulcer treatment market is set for growth driven by the increasing geriatric population. As individuals aged 65 or older are more susceptible to chronic diseases, including diabetes, cardiovascular issues, and cancer, specialized medical care becomes essential. Elderly individuals, despite comorbidities and dependencies, have a probability of healing from diabetes-related foot ulcers. The World Health Organization predicts a significant rise in the global geriatric population, reaching 1.4 billion individuals aged 60 or older by 2030, doubling to 2.1 billion by 2050. This demographic trend contributes to the growth of the diabetic foot ulcer treatment market as a result of age-related health challenges.
Technological advancement is a significant trend in the diabetic foot ulcer treatment market. Major players in the market are concentrating on innovative technologies, including cloud-based AI technology for the detection of diabetic foot ulcers. For example, in August 2024, Ipca Laboratories, an Indian multinational pharmaceutical company, launched the first-of-its-kind topical gel, Diulcus, specifically for diabetic foot ulcers (DFU) in India. Ipca has priced the Diulcus 15 mg gel at Rs 1365 per pack and will soon distribute it through its extensive network of 4,000 distributors across India.
Major companies in the diabetic foot ulcer treatment market are concentrating on introducing innovative solutions, such as ON101, to gain a competitive advantage. Innovative solutions for diabetic foot ulcer treatment encompass new and advanced methods for managing and healing foot ulcers in individuals with diabetes. For instance, in October 2023, Oneness Biotech Co., a Taiwan-based pharmaceutical firm, launched ON101, a novel cream (brand name Fespixon) designed for the topical treatment of diabetic foot ulcers (DFUs). The ON101 cream is an effective solution for chronic, non-healing DFUs that have not responded to conventional therapies. Clinical trial results show that the wound-healing cream is beneficial for diabetic foot ulcers, with participants reporting a 60% complete healing rate over 16 weeks, surpassing the 35% healing rate observed with absorbent wound dressings.
In August 2023, Coloplast, a Denmark-based company that creates products and services for individuals with medical conditions, acquired Kerecis for an undisclosed amount. Following the acquisition, both companies are collaborating to enhance and broaden the availability of innovative solutions for patients suffering from diabetic foot ulcers. Their combined product offerings present various wound care approaches, providing healthcare professionals with a wider range of options to address the specific needs of their patients. Kerecis is an Iceland-based company that specializes in treating diabetic foot ulcers using fish skin grafts.
Major companies operating in the diabetic foot ulcer treatment market are Coloplast A/S, Medtronic PLC, Molnlycke Health Care AB, B. Braun Melsungen AG, Medline Industries Inc., ConvaTec Inc., Acelity L.P. Inc., 3M Healthcare, Smith & Nephew PLC, Organogenesis Inc., BSN Medical GMBH, Integra LifeSciences Corporation, Derma Sciences Inc., Advancis Medical, Tissue Regenix Group PLC, MiMedx Group Inc., Kerecis, Human Regenerative Technologies LLC, AOTI Inc., Lohmann & Rauscher International GmbH & Co. KG, Urgo Medical, L&R USA Inc., Misonix Inc., Bioventus, Cellumed Co. Ltd.
North America was the largest region in the diabetic foot ulcer treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic foot ulcer treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the diabetic foot ulcer treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The diabetic foot ulcer treatment market includes revenues earned by entities by ultrasound therapy, negative pressure wound therapy, and active therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Diabetic Foot Ulcer Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on diabetic foot ulcer treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for diabetic foot ulcer treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The diabetic foot ulcer treatment market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.